Our speaker will be Professor Livia Hool, PhD FAHA
FCANZ, NHMRC Senior Research Fellow, President International Society for Heart
Research (Australasian Section)
She will be presenting 'Gene
therapy regime that restores mitochondrial function and prevents mdx
cardiomyopathy'
Livia Hool completed her PhD in
cellular electrophysiology at Royal North Shore Hospital, Sydney in 1995. She
then undertook 2 years postdoctoral research as a recipient of an American
Heart Association Postdoctoral Fellowship in the School of Medicine, Case
Western Reserve University, Cleveland, Ohio. In 1998 she was awarded a Peter
Doherty Fellowship from NHMRC and relocated to The University of Western
Australia where she established the Cardiovascular Electrophysiology Laboratory
in the Physiology Department. She has received continuous national competitive
funding since establishing the laboratory and previously held an NHMRC Career
Development Award and an ARC Future Fellowship. She is currently the recipient
of an NHMRC Senior Research Fellowship, Faculty-at-Large of the Victor Chang
Cardiac Research Institute in Sydney, President of the International Society
for Heart Research Australasian Section and Founding Director and General
Secretary of the Australian Cardiovascular Alliance. The work of her laboratory
is concerned with understanding the role that the L-type Ca2+
channel plays in mediating alterations in calcium and metabolic activity in the
heart leading to sudden cardiac death and heart failure. This is studied at the
level of purified channel protein, the single cell, the whole heart ex vivo and
in murine models of cardiomyopathy strategically directed towards building
basic knowledge, method development, discovery, and translation.
No comments:
Post a Comment